# Vaccine and Treatment Evaluation Units: Phase I Clinical Trial to Evaluate a Zika Vaccine Candidate

> **NIH NIH N01** · SAINT LOUIS UNIVERSITY · 2022 · $113,642

## Abstract

This program is comprised of a consortium of individual contracts within academic centers and organizations that provide a ready resource for the design and conduct of clinical trials to evaluate promising products to combat infectious diseases.  In general, products will be evaluated in normal healthy populations; however, access to special populations is also available.

## Key facts

- **NIH application ID:** 10656146
- **Project number:** 272201300021I-P00003-27200014-1
- **Recipient organization:** SAINT LOUIS UNIVERSITY
- **Principal Investigator:** SARAH GEORGE
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $113,642
- **Award type:** —
- **Project period:** 2013-09-16 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10656146

## Citation

> US National Institutes of Health, RePORTER application 10656146, Vaccine and Treatment Evaluation Units: Phase I Clinical Trial to Evaluate a Zika Vaccine Candidate (272201300021I-P00003-27200014-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10656146. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*